Effects of lovastatin on natural killer cell function and other immunological parameters in man
| Autor: | Malcolm G. Baines, Robert V. Zupkis, Alan Vost, Ruth McPherson, Hugh F. Pross, Chris Tsoukas, Michael Melino |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Interleukin 2
Adult Cytotoxicity Immunologic Male medicine.medical_specialty Lymphocyte medicine.medical_treatment T-Lymphocytes Immunology Hypercholesterolemia Lymphocyte proliferation Biology Lymphocyte Activation Natural killer cell Leukocyte Count Double-Blind Method Internal medicine medicine Immunology and Allergy Humans Lovastatin Phytohemagglutinins Aged B-Lymphocytes Middle Aged Hydroxymethylglutaryl-CoA reductase Lipids Killer Cells Natural medicine.anatomical_structure Endocrinology Cytokine HMG-CoA reductase biology.protein lipids (amino acids peptides and proteins) Female medicine.drug |
| Zdroj: | Journal of clinical immunology. 13(6) |
| ISSN: | 0271-9142 |
| Popis: | Suppression of cholesterol synthesis by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, such as lovastatin, has been shown to inhibit mitogen stimulated proliferation of natural killer (NK) cells and other lymphocytes in vitro. This effect is only partially overcome by provision of exogenous free or lipoprotein cholesterol but is reversed by mevalonate, suggesting that proliferating lymphocytes have a specific requirement for a nonsterol isoprenoid product of mevalonate. The effect of lovastatin (20 mg bid) on a range of immune function parameters was determined in a randomized, placebo-controlled, double-blind ex vivo study in 52 patients with primary hypercholesterolemia. No significant differences (P0.05) were found between lovastatin and placebo groups for basal NK or interleukin-2 (IL-2)-induced cell-mediated cytotoxicity, PHA-stimulated lymphocyte proliferation, or relative numbers of T lymphocytes (CD3+), B lymphocytes (CD19+), total NK cells (CD3-, CD16+, CD56+) and CD57+ NK cells or in immunoglobulin levels after 4 or 8 weeks of treatment. In contrast to previous in vitro data, no statistically or clinically significant changes were observed in any parameter of lymphocyte function in patients treated with lovastatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink